Browsing by Author "Fissolo, Nicolás Miguel"
Now showing items 1-5 of 5
-
Clinical practice of analysis of anti-drug antibodies against interferon beta and natalizumab in multiple sclerosis patients in Europe: A descriptive study of test results
Link, Jenny; Ramanujam, Ryan; Auer, Michael; Ryner, Malin; Hassler, Signe; Bachelet, Delphine; Fissolo, Nicolás Miguel; Montalban Gairín, Xavier; Comabella Lopez, Manuel (Public Library of Science, 2017-02-07) -
CSF Chitinase 3–Like 2 Is Associated With Long-term Disability Progression in Patients With Progressive Multiple Sclerosis
Borràs, Eva; Saiz, Albert; Martínez-Yélamos, Sergio; Pinteac, Rucsanda; Fissolo, Nicolás Miguel; Vidal Jordana, Angela; Montalban Gairín, Xavier; Sastre Garriga, Jaume; Comabella Lopez, Manuel; Villar, Luisa M (Lippincott Williams & Wilkins, 2021-11) -
CSF SERPINA3 Levels Are Elevated in Patients With Progressive MS
Fissolo, Nicolás Miguel; Matute Blanch, Clara; Osman, Mohamoud; Costa Riu, Carme; Pinteac, Rucsanda; Miró Cau, Berta; Sánchez Pla, Alex; Brito, Veronica Ines; Montalban Gairín, Xavier; Comabella Lopez, Manuel (Wolters Kluwer Health, 2021-03) -
Immunomodulatory Effects Associated with Cladribine Treatment
Fissolo, Nicolás Miguel; Calvo Barreiro, Laura; Eixarch Ahufinger, Herena; Boschert, Ursula; Espejo Ruiz, Carmen; Montalban Gairín, Xavier; Comabella Lopez, Manuel (MDPI, 2021-12) -
Serum Neurofilament Levels and PML Risk in Patients With Multiple Sclerosis Treated With Natalizumab
Fissolo, Nicolás Miguel; Pignolet, Beatrice; Rio Izquierdo, Jordi; Vermersch, Patrick; Ruet, Aurélie; deSèze, Jerome; Montalban Gairín, Xavier; Comabella Lopez, Manuel (Lippincott Williams & Wilkins, 2021-07)